Aria Neurosciences, Inc. (Aria) is an emerging biopharmaceutical company dedicated to developing and commercializing novel disease modifying therapies for Alzheimer’s disease (AD).
November 4, 2014 - Aria Neurosciences announced today that it received an Entrepreneur Innovation Award (EIA) from CTNext after presenting the Company's technology on October 23, 2014. The award provides $10,000 for innovative project ideas that help propel startups to the next level.
June 9, 2014 - Aria Neurosciences announces the publication of preclinical Alzheimer's Disease results with ARN-2966 (2-PMAP) in the Annals of Neurology. The data demonstrates that 2-PMAP has a unique mechanism of action in preventing cognitive defects in transgenic mice.
January 16, 2014 - Aria Neurosciences Signs Letter of Intent with Harvard/Massachusetts General Hospital (MGH) to establish a collaborative research agreement with the laboratory of Dr. Jack Rogers, a leading expert in field of Alzheimer’s disease.
December 19, 2013 - USPTO Issues Allowance of Aria Neurosciences Patent for Alzheimer’s Disease Compounds.
June 1, 2013 - Aria Neurosciences fills key leadership positions. Mark A. Findeis, Ph.D has joined as Corporate Research Advisor and Marc Silver has joined as Vice President of Business Operations. Please see more details under Management Bios.
CLICK TO READ MORE
June 18, 2012 - Hamden, CT: NYU/Aria Neurosciences abstract "An APP Translation Modulator ARN2966 Reduces Aß Deposition and Prevents Memory Deficit in AD Transgenic Mice" has been accepted for a symposium oral presentation....
May 1, 2011 - HAMDEN, CT: Aria Neurosciences, Inc. signed a license agreement with NYU School of Medicine for the intellectual property (IP) associated with the pending U.S. provisional patent application....